Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE ER versus GABAPENTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE ER versus GABAPENTIN.
DEPAKOTE ER vs GABAPENTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
Gabapentin is a structural analog of GABA but does not bind to GABA receptors. It binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters.
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
Initial dose: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate as needed up to 1800-3600 mg/day in three divided doses. Maximum single dose: 1200 mg. Dose adjustments for renal impairment should be made based on creatinine clearance.
None Documented
None Documented
Clinical Note
moderateGabapentin + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate."
Clinical Note
moderateGabapentin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Gabapentin."
Clinical Note
moderateGabapentin + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Gabapentin."
Clinical Note
moderateGabapentin + Clemastine
Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days
5-7 hours (normal renal function); prolonged to 50-140 hours in end-stage renal disease; half-life independent of dose due to linear kinetics.
Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%)
Renal: 76-81% unchanged in urine; biliary/fecal: <5% as metabolites; remainder (10-20%) as minor metabolites via urine.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine."